Wednesday, August 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source documentYahoo Finance· July 26, 2026

AT&T Beat on Earnings, Announced a $10 Billion Buyback, and Still Trades at 8 Times Earnings With a 4.6% Yield.

View original at finance.yahoo.com
AT&T Beat on Earnings, Announced a $10 Billion Buyback, and Still Trades at 8 Times Earnings With a 4.6% Yield. The market has spent years treating AT&T (NYSE: T) as a bond that happens to trade on an exchange…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

Data points we hold from this source

AT&T Inc. · stock price24.13 USD
AT&T Inc. · 52 week high29.79 USD
AT&T Inc. · pe ratio8 ratio
AT&T Inc. · fixed wireless customers added279000 customers
AT&T Inc. · adjusted ebitda margin39.1 percent
AT&T Inc. · planned shareholder returns total18 USD
AT&T Inc. · annual dividend total7.6 USD
AT&T Inc. · free cash flow4.7 USD
AT&T Inc. · fiber locations passed38.6 millions
AT&T Inc. · fiber customers added367000 customers
AT&T Inc. · diluted eps continuing ops0.66 USD_per_share
AT&T Inc. · internet customers added646000 customers
AT&T Inc. · annual dividend per share1.11 USD
AT&T Inc. · eps0.65 USD_per_share
AT&T Inc. · shares outstanding6.9 billions
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com